Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for ...

The report delivers a comprehensive analysis of global biologics sales. Covering cancer antibodies, non-TNF inflammatory mAbs, biosimilars, gene therapy, RNA-based drugs, and more, the report provides ...

Samsung Biologics, Hanmi Pharmaceutical Partner to Sell Prolia Biosimilar in Korea Samsung Bioepis and Hanmi Pharmaceutical ...

Greater Effectiveness and Enhanced Safety Profiles of Biosimilars Compared to Their Reference Biologics Increasing Their Adoption Worldwid ...

Overall, the study’s findings support the use of Amjevita and Imraldi as equally effective alternatives to Humira in the real ...

Alvotech and Dr. Reddy’s Announce FDA Acceptance of Biologic License Application for AVT03, a Proposed Biosimilar to Prolia® and Xgeva® Dr. Reddy’s Laboratories Ltd. (BSE: 500124 ...

Biologic License Application (BLA) submission for AVT03, developed by Alvotech, a proposed biosimilar of Prolia ® (denosumab) and Xgeva ® (denosumab). “The FDA's filing acceptance of Dr. Reddy ...

The label expansion couls help J&J establish Tremfya as a successor to Stelara, which is now facing a growing biosimilar ...

Dr. Reddy's Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, NSEIFSC: DRREDDY; along with its subsidiaries together referred to as "Dr. Reddy's") and Alvotech (NASDAQ: ALVO), a global biotech ...

Leinco Technologies offers high-purity research-grade biosimilar antibodies with the same specifications as many therapeutic antibodies. Therapeutic antibodies are widely used for the treatment of ...